Literature DB >> 24623488

Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history.

Ava Kwong1, Annie Tsz-Wai Chu, Christine Teen-Sum Wu, Desiree Man-Sik Tse.   

Abstract

Western studies have shown that the uptake rates of surveillance and prophylaxis may vary among BRCA mutation carriers between ethnicities. The present study is the first to investigate the behavioural impact and subjective attitudes in Southern Chinese high-risk families who had undergone BRCA1 and BRCA2 genetic testing up to 2.5 years post-testing. Individuals who had such genetic testing and have consented to participate in the prospective database of Hong Kong Hereditary Breast Cancer Family Registry were recruited and surveyed by a face-to-face or telephone interview. Sociodemographic information, genetic test results, pre- and post-testing surveillance, medical regimes, and attitudes towards the choice of clinical management were obtained by interviews and retrieval of medical records using this prospective database. 69 females with breast cancer history were recruited into the study. Twenty-nine female carriers (15 BRCA1 mutated gene-carriers and 14 BRCA2 mutated gene-carriers) and 40 non-carriers of a BRCA 1/2 mutations were interviewed. The uptake rate of high risk breast screening i.e. clinical breast examination, mammography, and breast MRI is significantly higher among female carriers (48.3 %) after knowing genetic testing results than before (p < 0.01). A strong significant relationship between any increase or decrease of ovarian ultrasound screening (OS) and genetic status is found (p < .001), with more females did OS and with a higher frequency after knowing genetic testing results among both carriers (22.7 % → 86.4 %) and non-carriers (37.5 % → 50.0 %). Among carriers, very few opted for prophylactic surgeries. The present cohort might see prophylaxis as last resort and would use traditional Chinese medicine in cancer risk management.

Entities:  

Mesh:

Year:  2014        PMID: 24623488     DOI: 10.1007/s10689-014-9706-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  48 in total

1.  Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.

Authors:  Niki J Agnantis; Evangelos Paraskevaidis; Dimitrios Roukos
Journal:  Ann Surg Oncol       Date:  2004-11-15       Impact factor: 5.344

2.  Disparities in breast cancer survival among Asian women by ethnicity and immigrant status: a population-based study.

Authors:  Scarlett Lin Gomez; Christina A Clarke; Sarah J Shema; Ellen T Chang; Theresa H M Keegan; Sally L Glaser
Journal:  Am J Public Health       Date:  2010-03-18       Impact factor: 9.308

3.  Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.

Authors:  Jeffrey R Botkin; Ken R Smith; Robert T Croyle; Bonnie J Baty; Jean E Wylie; Debra Dutson; Anna Chan; Heidi A Hamann; Caryn Lerman; Jamie McDonald; Vickie Venne; John H Ward; Elaine Lyon
Journal:  Am J Med Genet A       Date:  2003-04-30       Impact factor: 2.802

4.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

5.  Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.

Authors:  C Lerman; C Hughes; R T Croyle; D Main; C Durham; C Snyder; A Bonney; J F Lynch; S A Narod; H T Lynch
Journal:  Prev Med       Date:  2000-07       Impact factor: 4.018

6.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

7.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

Review 8.  Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review.

Authors:  M J Bermejo-Pérez; S Márquez-Calderón; A Llanos-Méndez
Journal:  Int J Cancer       Date:  2007-07-15       Impact factor: 7.396

Review 9.  The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Authors:  Victor G Vogel
Journal:  Expert Rev Anticancer Ther       Date:  2009-01       Impact factor: 4.512

Review 10.  National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up.

Authors: 
Journal:  Gynecol Oncol       Date:  1994-12       Impact factor: 5.482

View more
  2 in total

1.  Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience.

Authors:  Eliza Courtney; Xin Wei Chin; Jeanette Yuen; Shao-Tzu Li; Yanni Chen; John Carson Allen; Veronique Tan; Geok Hoon Lim; Joanne Ngeow
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

2.  Baseline knowledge and receptiveness to genetic testing for hereditary breast and ovarian cancer syndromes in Chinese high-risk females.

Authors:  Annie Tsz-Wai Chu; Desiree Man-Sik Tse; Dacita To Ki Suen; Ava Kwong
Journal:  J Community Genet       Date:  2021-04-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.